' 
INTRODUCTION
After marketing authorisation has been obtained for immunological veterinary medicinal products (IVMPs), these must be produced in accordance with the principles of 'good manufacturing practice' (GMP) as stated in European Economic Community (EEC: now European Union [EU]) Directive 91/412/EEC (2) . This means that all the production stages have to be performed under very strict conditions. The biological domain of pharmaceutical product manufacture differs from the manufacture of other medicinal products in the following specific ways:
-The active ingredient is almost always produced by the manufacturer.
-It is necessary to handle living organisms, some of which may be pathogenic for humans and/or animals.
-The range of products is wide, due to the large number of animal species and related pathogenic agents.
The specific risks to be assessed throughout the manufacturing process are discussed below.
PRODUCTION STAGES
The three main stages in the vaccine production process (Fig. 1) are described below.
Preparation of active ingredients
Active ingredient preparation is one of the most crucial stages of the production process and involves handling various starting materials, including the following:
-living organisms -cell substrates -media supplemented with substances of animal origin -water.
All these elements are at risk.
The main culture and other stages -such as harvest, separation, concentration, extraction, purification, inactivation (killed products), and all downstream processesmust be conducted in suitably-adapted working premises with appropriate, controlled and calibrated equipment (6, 7) . Personnel must be properly trained (qualified) and provided with the appropriate (protective) clothing. All the elements involved herepersonnel, working area, equipment and starting materials -are at risk.
Formulation
This stage appears to be less critical in terms of risk. Formulation involves the addition of active ingredient(s) to adjuvants and/or stabilisers and preservatives. The specific process consists in either emulsion (oil-adjuvanted products) or blending. The requirements for personnel, premises and equipment are identical to those for the preparation of active ingredients.
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This stage includes the following types of operations:
-open stages (e.g. filling and freeze-drying), which require the same precautionary measures against potential contamination as those described above for active ingredient preparation and formulation; -closed stages (e.g. labelling and storage), where the major risk is incorrect identification of a product.
Other considerations
For freeze-dried products, reconstitution is required at the time of administration. Some diluents consist of substances of animal origin which therefore represent the same risks outlined for the previous stages.
The correct use of the product (dose, route of administration, etc.) and the associated risks are the responsibility of the veterinarian, provided that the instruction leaflet is sufficiently clear.
RISKS AND ASSESSMENTS
Starting material
Live materials
Seed lots
The mass production of IVMPs obtained from microbial cultures is based on a seed lot system (3, 4, 8 Seed lots should be adequately characterised and tested for contaminants. The test for contaminants must be as complete as possible. For each master seed lot or working seed lot, a specific file should be kept, describing all the tests performed and recording the results.
The list of potential contaminants is documented primarily in terms of the animal species of origin (as far as this is known), and possibly in terms of the animal species which will eventually be vaccinated (if not the same as the species of origin of the product) (9) .
Another risk is the misuse of a master seed lot or working seed lot. For this reason, each seed lot should be stored, identified and used in such a way as to minimise the risks of contamination or alteration. Storage containers should be hermetically sealed and clearly labelled.
Cell substrates a) Cell-lines
At present, most viral amplifications are obtained on cell-lines. These productions are based on a cell bank system. Master cell banks and working cell banks are controlled and validated before any use for pilot and industrial productions.
The major risk for seed lots is also contamination by an unexpected agent. The contamination could arise from within the original cells or may possibly be introduced by additional media or handling. Cells and animals are tested for specific contaminants. For example, the list of potential contaminants of the VERO cell-line -currently used for the amplification of many viruses (human and veterinary) -is rather impressive.
b) Primary cells
No longer in common use, primary cells are required for the multiplication of some viral agents. As with cell-lines, there is obviously a risk of contamination by a viral or bacterial agent. The cells should be obtained from specific pathogen-free (SPF) animals which have been carefully and regularly tested for contaminants. The production cells are also carefully tested, although the results of these tests may be obtained after their use in the manufacturing process. Release of the final product, however, is conditional on satisfactory results of the tests.
c) SPF eggs
Avian live vaccines are prepared on SPF eggs or SPF chicken embryo fibroblasts. The risk of contamination and the means of assessment of this risk are the same as those described above for other live materials. SPF laying birds are carefully monitored, and purity controls must be reinforced for this type of vaccines, as stated in the relevant European Pharmacopoeia (EP) monographs. The monograph on avian live infectious bronchitis vaccine (1) may be cited as an example.
Non-living materials
Media
Amplification of living organisms (viruses, bacteria) requires specific media prepared with various chemical substances and antibiotics. Some of these products are covered by a specific EP monograph, and therefore raise no problems.
a) EP registered products
Media covered by specific EP monographs include sodium hydrogen carbonate, sodium chloride, disodium phosphate dihydrate, gentamicin sulphate, kanamycin acid sulphate, aluminium hydroxide and sucrose.
b) Non-EP registered products
Monopotassium phosphate, vancomycin hydrochloride, sodium glutamate, polyoxyethylene fatty acid, ether of fatty alcohols and of polyols, etc. are controlled using in-house techniques, and (when possible) in accordance with EP monographs.
c) Commercial media
These media (e.g. MEM, RPMI) are prepared, controlled and distributed by commercial suppliers, and are sterilised by filtration.
None of these defined products presents high risks in the production of IVMPs.
Substances of animal origin
Amplification of viruses and bacteria requires media and additional substances of animal origin, i.e. sera, peptones and/or protein hydrolysates. Most of these media and other substances are of bovine origin.
This kind of material represents the major risk in the production of IVMPs. Two types of potential contaminants must be considered, namely conventional agents and non-conventional agents.
a) Conventional agents
Two approaches are currently used for the treatment of substances of animal origin, namely inactivation of potential contaminants by inactivants (mainly ß-propriolactone) and, more recently, gamma-ray irradiation. For the latter approach, one of two processes may be used:
The product is arranged at fixed locations around the radiation source and cannot be loaded or unloaded while the radiation source is exposed.
ii) Continuous mode
An automatic system conveys the products into the radiation cell, past the exposed radiation source (along a defined path and at an appropriate speed) and out of the cell.
It is important to establish the amount of radiation necessary to inactivate the suspected contaminating viruses, to ensure effective treatment and minimise deleterious side-effects.
In both cases, treatments must be validated. It has been defined that the treatment should eliminate the potential agent or reduce its titre by at least 10 6 ID 50 (50% infective dose) (3).
b) Non-conventional agents (prions)
There is a risk that substances of bovine, ovine and caprine origin may be contaminated with an agent responsible for spongiform encephalopathy, and great care must be taken in choosing the source of such substances for use in the manufacture of IVMPs.
Adequate measures to assess such a risk include selection of the geographical origin of the product (i.e. the product must not come from an infected country) and selection of the appropriate type of tissue, when possible, in accordance with the official classification of tissues. Bovine material should not be used in products for species (e.g. cattle, sheep, goats) which are known to be naturally susceptible to bovine spongiform encephalopathy (BSE), scrapie, or similar diseases.
Water
Preparation of media requires 'ultrafiltered' or, preferably, distilled water. If water purity is monitored according to the appropriate EP monographs, the only specific risk is potential bacterial contamination, which will be detected by several sterility tests (on the water batch itself or, later, on the active ingredient and the finished product). Treated water should be monitored regularly for chemical and biological contamination.
Final containers and stoppers
Glass containers
A specific EP monograph distinguishes between type I and type II glass containers, on the basis of hydrolytic resistance.
Plastic containers
The quality of polypropylene is covered by a specific EP monograph.
Stoppers
Butyl stoppers are controlled using in-house techniques.
None of the above elements presents any risk, except to the product (e.g. heavy metal ions could be released, potentially damaging the live vaccinal agent).
Personnel
Documentation
Personnel should know and regularly consult all technical documentation (see below).
Training
For all production and control stages, the manufacturer should select personnel with the necessary qualifications and practical experience. Specific training should be provided to all personnel involved in production areas or in control units, and to other personnel whose activities could affect the quality of the product. Detailed hygiene programmes should be established and adapted to the different needs within the plant. All personnel should undergo a medical examination upon recruitment, and at regular intervals thereafter.
Clothing
Personnel should wear clothing of a type and quality appropriate for the process being performed and the working area, to protect the product from contamination (Fig. 2) . Clothing should be appropriate for the air grade of the area where the personnel will be working. It may be useful for clothing worn in open operations areas to be of a different colour from that worn in closed systems areas.
Working areas
General considerations
Production of sterile IVMPs should be conducted in 'clean' areas, where both personnel and goods enter through airlocks. 'Clean' areas should be maintained to an appropriate standard of cleanliness and supplied with air which has been thoroughly filtered to an appropriate degree. The specific question of controlled areas represents the second most important problem in terms of risk.
Each manufacturing operation requires an appropriate level of air cleanliness to minimise the risks of particulate or microbial contamination of the product or materials being handled (6, 7, 10) .
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Protective clothing worn to harvest live virus using grade A/B equipment Live biological agents should be handled in contained areas. The level of containment should depend on the pathogenicity of the microorganism and whether it has been classified as exotic for the country concerned.
Inactivated biological agents should be handled in 'clean' areas.
Non-infected cells isolated from multicellular organisms and filtration-sterilised media should also be handled in 'clean' areas.
Open circuit operations involving products or components not subsequently sterilised should be carried out under a grade A laminar air-flow work station in a grade B area (both graded in accordance with European GMP, on the basis of the size of particles and the number per cubic metre).
Contained premises should be easily disinfected and must have the following characteristics: a) no direct venting to the exterior b) ventilation with air at negative pressure and air extraction through 'high-efficiency particulate air' (HEPA) filters (two sets of HEPA filters in series for areas where exotic organisms or pathogenic agents are handled) c) system for collection and treatment of liquid effluents d) procedure for sterilisation or incineration of solid wastes e) changing rooms designed and used as airlocks, equipped with washing and showering facilities f) airlock system for the transit of equipment g) barrier double-door autoclave to secure removal of waste material and introduction of sterile items h) specific areas for very resistant agents i) thorough disinfection between production campaigns using different vaccinal viruses.
Requirements for the installation and maintenance of production areas
In 'clean' areas, all exposed surfaces should be smooth and impervious to avoid accumulation of dust, particles or microorganisms. The surfaces should be easily cleaned and disinfected. The installation of pipes and ducts should not create recesses, while installation of sinks and drains should be avoided. Changing rooms should be designed as airlocks, and used to provide separation of the different stages of changing; this will help to minimise microbial and particulate contamination of protective clothing. A filtered air supply should maintain a positive pressure relative to surrounding areas. It should be demonstrated that air-flow patterns do not present a contamination risk (e.g. no spread of particles from persons, operations [e.g. inoculation, harvest, concentration, purification], machines, etc.). A warning system should be provided to indicate failure in the air supply. Indicators of pressure differences should be fitted between areas where these differences are important. Pressure differences should be recorded regularly.
Sanitation of 'clean' areas is particularly important, and should be performed frequently. Appropriate, validated disinfectants and detergents should be used. Fumigation may be useful to reduce microbiological contamination. Clean areas should be monitored by means of microbial counts at planned intervals, and the results should be considered when determining batch release (6,7,10).
Equipment and sterilisation
Production equipment (fermenters, inactivators, containers, vessels, concentration and filtration devices and, indeed, any apparatus involved in sterile production) should be carefully decontaminated and sterilised before use. The equipment should be handled carefully after the final cleaning process, to prevent recontamination (Fig. 3) .
The efficacy of all washing, decontamination and sterilisation procedures should be validated, and validation repeated at regular intervals thereafter, and when any significant change is made in the process or equipment. The heat cycle used in sterilisation should be recorded. Generally, if the product cannot be sterilised by heat in the final container, solutions or liquids should be filtered through a sterile filter of nominal pore size (0.22 u).
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In view of the wide variety of products, the large number of stages involved in the manufacture of IVMPs, and the nature of the biological processes, careful attention must be paid to all operating procedures and their validation. This involves constant inprocess monitoring of all completed stages of production.
Many different stages or processes are involved, e.g. inoculation, culture, harvest, separation, concentration, extraction, purification, inactivation, blending, formulation, filling, freeze-drying and labelling.
Most of these processes require transfer of materials (e.g. sterile media, cultures, active ingredients, bulks or final products), which should be performed in a presterilised closed system. Where this is not possible, transfer operations must be protected by laminar air-flow work stations. Care must be taken to ensure that vessels are correctly connected when cultures are added.
Inactivation
Inactivation is the third critical stage in manufacturing killed IVMPs. Several of the steps involved must be under perfect control. The inactivation process includes the transfer of the product from the first vessel to the second after addition of the inactivant. In principle, products are inactivated following addition of inactivant accompanied by sufficient stirring. The inactivation kinetics must be established during the development of the inactivation process, and inactivation must be checked by personnel responsible for quality control (careful testing of samples, and evaluation of their representativity for validating storage, filtration, inactivant, neutralisation; these are absolutely necessary elements).
Filling and freeze-drying
Filling and freeze-drying are two open operations where there may be a risk of viral or bacterial contamination. Containers for bulk product should be sealed prior to filling, appropriately labelled and stored under specified conditions of temperature.
The product should be placed in bulk containers as soon as possible after production. There should be a system to ensure that containers do not leak and are properly sealed after filling.
Freeze-dryers should be loaded in an appropriate 'clean'/contained area. Doubledoor freeze-dryers should be sterilised after each cycle unless opened in a 'clean' area. When this equipment is being operated as part of a production campaign using a specific vaccinal virus, it should be sterilised at least after each campaign.
Labelling
Labelling is the last operation before shipping. An error of labelling can be a real problem in the field, as the vaccine might be used in a species other than that for which it is intended. Care must be taken to avoid such errors and particularly to check packaging chains before and after packaging.
QUALITY CONTROL AND QUALITY ASSURANCE
As noted above, quality control and quality assurance are always present and necessary.
Quality control
Quality control forms part of GMP, and is concerned with sampling, specifications and testing. Documentation ensures that the necessary relevant and validated tests have been performed (5).
In-process control
In-process control is obligatory, and is useful for starting materials and for important stages of downstream processing and formulation. In addition to the classic controls of sterility and dosages, some in-process controls are particularly important, e.g. purity and inactivation testing (see above).
Final controls
All controls on the finished product (e.g. physicochemical tests for sterility, identity, purity, safety, titration or potency) should be listed in the registration file (5).
Quality assurance
Quality assurance consists of planned and systematic actions necessary to provide adequate confidence in a product, and to prove that it will satisfy quality requirements. Quality in design and production ('good laboratory practice' [GLPJ plus GMP), using formal quality assurance procedures, ultimately provides the best guarantee for the quality of IVMPs.
Four main domains are currently covered by quality assurance, as outlined below.
Documentation
All general and specific operations, instructions, processes, tests, etc. must be precisely described and documented in a specific form known as 'standard operating procedures' (SOP).
All documents, specifications, manufacturing formulae, records and SOPs should be designed, prepared, reviewed and distributed with care. They should be approved, signed and dated by appropriate and authorised persons, and all records should be kept up to date.
Records of processing and packaging provide a history of each batch of product, including distribution and any relevant circumstances or deviations pertinent to the quality of the finished product.
Training
All personnel employed in areas where IVMPs are manufactured should be given training in hygiene and microbiology. Responsible personnel should be formally trained in one or all of the following fields: bacteriology, biology, biochemistry, immunology, medicine, virology and veterinary medicine.
Internal audits
Internal auditing is certainly one of the most useful and powerful tools to improve quality in the production of IVMPs. The main purposes are as follows:
-to compare what is observed with what is expected and/or specified -to conduct a continuous critical analysis of the unit organisation and the handled documents -to enable quality control by applying GMP.
Defects observed during internal audits are classified as critical, major or minor. The follow-up of these audits is important and should be carefully organised.
Validation
For all processes and analytical tests, validation studies should reinforce GMP and should be conducted in accordance with defined procedures. Results and conclusions should be recorded.
When any new manufacturing formula or method of preparation is adopted, the defined process, using the materials and equipment specified, should be shown to yield a product of the required quality. The effect of significant amendments on the manufacturing process or analytical tests should be verified. Processes and procedures should be tested regularly to ensure that they remain capable of achieving the intended results.
Batch release by the 'qualified person'
The role of the 'qualified person' is to provide an independent review of the entire manufacture of the product, and to determine the suitability of the product for release by examining the manufacturing procedures and test systems to the extent required by the quality assurance/quality control scheme. The 'qualified person' is better able to assess data relating to individual batches than the producer or controller, as the former operates independently.
When the 'qualified person' has performed this independent review and taken the responsibility for releasing a batch, the batch will be released on the basis of the following documents: a) from the manufacturer:
-batch protocol -release document;
b) from the competent authority: -test result -release certificate.
As each IVMP manufacturing plant is regularly inspected, the 'qualified person' releases a batch of product and submits documents to the competent authority. With regular inspection, there is some degree of confidence: the competent authority does not need to control the product and accepts the manufacturer's batch release with the submitted documents. The competent authority checks that the batch record contains all relevant information on the production and quality control testing of the batch.
The batch is finally released by the competent authority. This is the final and official approval.
CONCLUSION
This study has concentrated on several points which represent risks in the production of IVMPs. Maximum security is ensured by in-process controls and final control, combined with GMP and quality assurance. The strong points of GMP are as follows:
-assessment of potential cross-contamination and possible confusion -batch system production -batch documentation -processes and analytical methods -validation (mainly of processes and analytical methods) -independent examination of all data by the 'qualified person', leading to batch release. 
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